questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du sang
Immunoprotéines
Protéines du système du complément
Enzymes activatrices du complément
Complement C3-C5 Convertases
Complement C3-C5 Convertases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Déficience du complément
Tests de laboratoire
Tests de complément
Hémolyse
Infections
Maladies auto-immunes
Sérum
Activité enzymatique
Symptômes
5
Éruptions cutanées
Douleurs articulaires
Troubles neurologiques
Inflammation cérébrale
Infections bactériennes
Maladies auto-immunes
Déficience du complément
Symptômes cliniques
Prévention
5
Prévention
Diagnostic précoce
Alimentation équilibrée
Nutrition
Suivi médical
Complications
Conseils génétiques
Transmission héréditaire
Traitements
5
Immunoglobulines
Antibiotiques
Médicaments anti-inflammatoires
Inhibiteurs du complément
Transfusions sanguines
Protéines du complément
Thérapie génique
Déficiences génétiques
Médecine personnalisée
Soins individualisés
Complications
5
Infections graves
Maladies auto-immunes
Complications réversibles
Gestion des complications
Qualité de vie
Douleurs chroniques
Complications neurologiques
Troubles cognitifs
Lésions tissulaires
Réactions inflammatoires
Facteurs de risque
5
Antécédents familiaux
Maladies auto-immunes
Infections fréquentes
Déficience du complément
Maladies génétiques
Prédisposition
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Complement C3-C5 Convertases : Questions médicales les plus fréquentes",
"headline": "Complement C3-C5 Convertases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Complement C3-C5 Convertases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-14",
"dateModified": "2025-03-09",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Enzymes activatrices du complément",
"url": "https://questionsmedicales.fr/mesh/D003166",
"about": {
"@type": "MedicalCondition",
"name": "Enzymes activatrices du complément",
"code": {
"@type": "MedicalCode",
"code": "D003166",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D050578",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050578",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alternative pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051561",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051561",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.374"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Alternative pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Alternative Pathway",
"url": "https://questionsmedicales.fr/mesh/D051566",
"about": {
"@type": "MedicalCondition",
"name": "Alternative pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051566",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.500.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D050579",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050579",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Classical pathway complement C3 convertase",
"alternateName": "Complement C3 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051574",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway complement C3 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051574",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Classical pathway C5 convertase",
"alternateName": "Complement C5 Convertase, Classical Pathway",
"url": "https://questionsmedicales.fr/mesh/D051577",
"about": {
"@type": "MedicalCondition",
"name": "Classical pathway C5 convertase",
"code": {
"@type": "MedicalCode",
"code": "D051577",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.750.750"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"alternateName": "Mannose-Binding Protein-Associated Serine Proteases",
"url": "https://questionsmedicales.fr/mesh/D050606",
"about": {
"@type": "MedicalCondition",
"name": "Mannose-Binding Protein-Associated Serine Proteases",
"code": {
"@type": "MedicalCode",
"code": "D050606",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.124.486.274.045.387.875"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Complement C3-C5 Convertases",
"alternateName": "Complement C3-C5 Convertases",
"code": {
"@type": "MedicalCode",
"code": "D050577",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "John D Lambris",
"url": "https://questionsmedicales.fr/author/John%20D%20Lambris",
"affiliation": {
"@type": "Organization",
"name": "Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA."
}
},
{
"@type": "Person",
"name": "Tom Eirik Mollnes",
"url": "https://questionsmedicales.fr/author/Tom%20Eirik%20Mollnes",
"affiliation": {
"@type": "Organization",
"name": "Research Laboratory, Nordland Hospital, 8092 Bodø, Norway."
}
},
{
"@type": "Person",
"name": "Dimitrios C Mastellos",
"url": "https://questionsmedicales.fr/author/Dimitrios%20C%20Mastellos",
"affiliation": {
"@type": "Organization",
"name": "National Center for Scientific Research 'Demokritos', Athens, Greece."
}
},
{
"@type": "Person",
"name": "Giuseppe Remuzzi",
"url": "https://questionsmedicales.fr/author/Giuseppe%20Remuzzi",
"affiliation": {
"@type": "Organization",
"name": "Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy."
}
},
{
"@type": "Person",
"name": "Markus Huber-Lang",
"url": "https://questionsmedicales.fr/author/Markus%20Huber-Lang",
"affiliation": {
"@type": "Organization",
"name": "Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Particle sorting to improve the removal of fluoride and aluminum nitride from secondary aluminum dross by roasting.",
"datePublished": "2023-03-06",
"url": "https://questionsmedicales.fr/article/36872407",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11356-023-26201-3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of a novel aluminum lactate-based with an aluminum chloride-based antiperspirant in excessive axillary and inguinal perspiration: first randomized controlled trial.",
"datePublished": "2022-12-10",
"url": "https://questionsmedicales.fr/article/36495093",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/ddg.14898"
}
},
{
"@type": "ScholarlyArticle",
"name": "Application of PAT Probes in Aluminum Phosphate Adjuvant Manufacturing.",
"datePublished": "2023-12-19",
"url": "https://questionsmedicales.fr/article/38114802",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11095-023-03642-6"
}
},
{
"@type": "ScholarlyArticle",
"name": "Aluminum Phosphide Poisoning, an Institutional Experience: Case Series.",
"datePublished": "2022-06-02",
"url": "https://questionsmedicales.fr/article/35945885",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.33314/jnhrc.v20i01.3607"
}
},
{
"@type": "ScholarlyArticle",
"name": "Surface Plasmon Resonance Sensitivity Enhancement Based on Protonated Polyaniline Films Doped by Aluminum Nitrate.",
"datePublished": "2022-12-03",
"url": "https://questionsmedicales.fr/article/36551089",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/bios12121122"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du sang",
"item": "https://questionsmedicales.fr/mesh/D001798"
},
{
"@type": "ListItem",
"position": 5,
"name": "Immunoprotéines",
"item": "https://questionsmedicales.fr/mesh/D007162"
},
{
"@type": "ListItem",
"position": 6,
"name": "Protéines du système du complément",
"item": "https://questionsmedicales.fr/mesh/D003165"
},
{
"@type": "ListItem",
"position": 7,
"name": "Enzymes activatrices du complément",
"item": "https://questionsmedicales.fr/mesh/D003166"
},
{
"@type": "ListItem",
"position": 8,
"name": "Complement C3-C5 Convertases",
"item": "https://questionsmedicales.fr/mesh/D050577"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Complement C3-C5 Convertases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Complement C3-C5 Convertases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-04",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Complement C3-C5 Convertases",
"description": "Comment diagnostiquer une déficience en convertases C3-C5 ?\nQuels tests sont utilisés pour évaluer l'activité du complément ?\nQuels signes cliniques suggèrent une activation du complément ?\nPeut-on mesurer l'activité des convertases dans le sang ?\nQuels marqueurs biologiques sont associés aux convertases ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Aluminum+Compounds#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Complement C3-C5 Convertases",
"description": "Quels symptômes indiquent une activation excessive du complément ?\nComment se manifestent les troubles liés aux convertases ?\nLes troubles du complément causent-ils des symptômes neurologiques ?\nQuels signes indiquent une déficience en C3 ?\nLes symptômes varient-ils selon le type de déficience ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Aluminum+Compounds#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Complement C3-C5 Convertases",
"description": "Peut-on prévenir les déficiences en complément ?\nQuelles mesures préventives peuvent réduire les infections ?\nLes patients doivent-ils éviter certains aliments ?\nComment le suivi médical aide-t-il à prévenir les complications ?\nLes conseils génétiques sont-ils utiles pour les familles ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Aluminum+Compounds#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Complement C3-C5 Convertases",
"description": "Quels traitements sont disponibles pour les déficiences en complément ?\nComment traiter une activation excessive du complément ?\nLes transfusions sanguines aident-elles en cas de déficience ?\nY a-t-il des thérapies géniques pour les déficiences en complément ?\nLes traitements sont-ils personnalisés selon le patient ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Aluminum+Compounds#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Complement C3-C5 Convertases",
"description": "Quelles complications peuvent survenir avec une déficience en C3 ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nLes complications neurologiques sont-elles fréquentes ?\nQuelles sont les complications liées à l'activation excessive du complément ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Aluminum+Compounds#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Complement C3-C5 Convertases",
"description": "Quels facteurs augmentent le risque de déficience en complément ?\nL'âge influence-t-il le risque de troubles du complément ?\nLes infections fréquentes sont-elles un facteur de risque ?\nLe sexe joue-t-il un rôle dans les troubles du complément ?\nLes maladies génétiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D050577?mesh_terms=Aluminum+Compounds#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une déficience en convertases C3-C5 ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de C3 et C5 peuvent indiquer une déficience."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'activité du complément ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'hémolyse et les dosages de protéines du complément sont courants."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques suggèrent une activation du complément ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des infections récurrentes ou des maladies auto-immunes peuvent indiquer une activation."
}
},
{
"@type": "Question",
"name": "Peut-on mesurer l'activité des convertases dans le sang ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des tests spécifiques peuvent évaluer l'activité des convertases dans le sérum."
}
},
{
"@type": "Question",
"name": "Quels marqueurs biologiques sont associés aux convertases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux de C3a et C5a, produits de clivage, sont des marqueurs importants."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une activation excessive du complément ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme des éruptions cutanées, des douleurs articulaires et de la fièvre peuvent survenir."
}
},
{
"@type": "Question",
"name": "Comment se manifestent les troubles liés aux convertases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Ils peuvent se manifester par des infections fréquentes et des réactions inflammatoires."
}
},
{
"@type": "Question",
"name": "Les troubles du complément causent-ils des symptômes neurologiques ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles neurologiques peuvent survenir en raison d'une inflammation cérébrale."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une déficience en C3 ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections bactériennes récurrentes et des maladies auto-immunes peuvent être des signes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de déficience ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon que la déficience concerne C3 ou C5."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les déficiences en complément ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est difficile, mais un diagnostic précoce peut aider à gérer les symptômes."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire les infections ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations et une bonne hygiène peuvent aider à réduire le risque d'infections."
}
},
{
"@type": "Question",
"name": "Les patients doivent-ils éviter certains aliments ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'y a pas de restrictions alimentaires spécifiques, mais une alimentation équilibrée est conseillée."
}
},
{
"@type": "Question",
"name": "Comment le suivi médical aide-t-il à prévenir les complications ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un suivi régulier permet d'identifier et de traiter rapidement les complications potentielles."
}
},
{
"@type": "Question",
"name": "Les conseils génétiques sont-ils utiles pour les familles ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les conseils génétiques peuvent aider à comprendre les risques de transmission."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les déficiences en complément ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des immunoglobulines intraveineuses et des antibiotiques prophylactiques."
}
},
{
"@type": "Question",
"name": "Comment traiter une activation excessive du complément ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments anti-inflammatoires et des inhibiteurs du complément peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Les transfusions sanguines aident-elles en cas de déficience ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les transfusions peuvent aider à restaurer les niveaux de protéines du complément."
}
},
{
"@type": "Question",
"name": "Y a-t-il des thérapies géniques pour les déficiences en complément ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des recherches sont en cours sur les thérapies géniques pour traiter ces déficiences."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements sont souvent adaptés en fonction des besoins individuels du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une déficience en C3 ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des infections graves, des maladies auto-immunes et des complications rénales peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais d'autres peuvent être permanentes."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en entraînant des douleurs chroniques et des limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Les complications neurologiques sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications neurologiques peuvent survenir, notamment des troubles cognitifs."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications liées à l'activation excessive du complément ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions tissulaires et des réactions inflammatoires peuvent se produire."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de déficience en complément ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents familiaux et certaines maladies auto-immunes augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque de troubles du complément ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque peut augmenter avec l'âge en raison de la dégradation du système immunitaire."
}
},
{
"@type": "Question",
"name": "Les infections fréquentes sont-elles un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des infections fréquentes peuvent indiquer une déficience sous-jacente du complément."
}
},
{
"@type": "Question",
"name": "Le sexe joue-t-il un rôle dans les troubles du complément ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines déficiences sont plus fréquentes chez les femmes en raison de facteurs hormonaux."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques peuvent prédisposer à des déficiences du complément."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 09/03/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Department of Laboratory Medicine and Pathology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
5 publications dans cette catégorie
Affiliations :
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
K.G. Jebsen Thrombosis Research and Expertise Center, University of Tromsø, 9037 Tromsø, Norway.
Department of Immunology, Oslo University Hospital, University of Oslo, 0318 Oslo, Norway.
Centre of Molecular Inflammation Research, Norwegian University of Science and Technology, 7491 Trondheim, Norway; and.
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
National Center for Scientific Research 'Demokritos', Athens, Greece.
Publications dans "Complement C3-C5 Convertases" :
5 publications dans cette catégorie
Affiliations :
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
L. Sacco Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy.
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Institute of Clinical and Experimental Trauma Immunology, University Hospital of Ulm, Ulm, Germany.
Publications dans "Complement C3-C5 Convertases" :
4 publications dans cette catégorie
Affiliations :
Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Department of Immunology, Genetics and Pathology, University Uppsala, Uppsala, Sweden.
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Publications dans "Complement C3-C5 Convertases" :
3 publications dans cette catégorie
Affiliations :
Centre de Recherche des Cordeliers, INSERM, Sorbonne Université, Université de Paris, Paris, France.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Linneaus Center for Bomaterials Chemistry, Linnaeus University, Kalmar, Sweden.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Deparment of Infection Biology, Leibniz Institute for Natural Product Research and Infection Biology, Jena, Germany.
Faculty of Life Sciences, Friedrich Schiller University Jena, Jena, Germany.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Research Laboratory, Nordland Hospital, 8092 Bodø, Norway.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Biomedicine, Aarhus University, DK-8000 Aarhus, Denmark.
Publications dans "Complement C3-C5 Convertases" :
2 publications dans cette catégorie
Affiliations :
Department of Molecular Biology and Genetics, Aarhus University, DK-8000 Aarhus, Denmark; gra@mbg.au.dk.
Publications dans "Complement C3-C5 Convertases" :
It is important to remove active substances from secondary aluminum dross (SAD) to meet the reuse of SAD. In this work, the removal of active substances from different particle sizes of SAD was studie...
Topical aluminum salts are a commonly used remedy for excessive axillary perspiration. To the contrary, less is known about their anhidrotic potential in the groin. This study sought to compare the an...
Fifty participants were enrolled in this open open-labeled, randomized, controlled trial. Following a baseline assessment, efficacy was analyzed at two time points throughout the study period by means...
Both study preparations were comparably effective in reducing axillary and inguinal perspiration and exhibited increasing effectiveness over time. In both treatment regions, the aluminum lactate-based...
Due to its comparable efficacy and - most noticeably in the groin - superior tolerability, this study supports the use of topical aluminum lactate as a first-line option to control excessive axillary ...
This study is focused on monitoring process parameters and quality attributes of aluminum phosphate (AlPO...
The manufacturing of aluminum adjuvant suspension was monitored at manufacturing scale using conductivity, turbidity, infrared, and particle sizing and count probes to follow the continuous evolution ...
The data showed that AlPO...
The results of this study showed the usefulness of the in-line probes to automate continuous assessment of AlPO...
The growing concern over pesticide use has been linked to self-harm and suicide especially in agricultural countries like Nepal. Pesticides like organophosphorus and aluminum phosphide cause the major...
This hospital record-based study includes Aluminum phosphide poisoning patients presenting to the emergency department of Scheer Memorial Adventist Hospital from first January 2017 to 31st December 20...
Out of 25 total poisoning cases, most of them were female (60%) and married (56%). The case fatality rate was 84% among which 20% cases were brought dead while 64% died in the hospital. All poisoning ...
Herein we report a case series on 25 Aluminum phosphide poisoning cases with high case fatality rate and all cases being suicidal in intent....
Complex composite films based on polyaniline (PANI) doped hydrochloric acid (HCl) incorporated with aluminum nitrate (Al(NO...
α-Tocotrienol is one of the major constituents of palm oil. It is a well-known antioxidant and cholesterol-lowering neuroprotectant. To prevent the initiation of Alzheimer's like symptoms, much attent...
Aluminum phosphide (rice tablet) is a highly efficient agent for preserving grains against rodents and insects. It accounts for a large number of poisoning cases. Aluminum phosphide poisoning has a hi...
We report the case of a 30-year-old Iranian woman with critical aluminum phosphide poisoning, presented with hypotension and other signs of shock and severe metabolic acidosis, successfully treated wi...
Aluminum phosphide poisoning has a high mortality rate, and to date, no antidote is available. Administration of high-dose intravenous regular insulin and dextrose is suggested as a potential life-sav...
Complexation of nicotine (NCT) and magnesium aluminum silicate (MAS) has been formed in the dispersions that required multiple preparation steps. In this study, physical blending was used to produce N...
The use of metal phosphides, particularly aluminum phosphide, poses a significant threat to human safety and results in high mortality rates. This study aimed to determine mortality patterns and predi...
Aluminum phosphide toxicity is a serious problem in many countries. Unfortunately, there is no specific antidote. N-acetylcysteine has been used in some studies as adjuvant therapy depending on to its...
We searched in PubMed, Scopus, Web of Science, and Cochrane Library databases. We only included randomized controlled trials that assessed the efficacy of IV N-acetylcysteine and supportive treatment ...
We included four randomized controlled trials with 177 patients. 91 patients were distributed in N-acetylcysteine group and 86 patients in the control group. Mortality rates in N-acetylcysteine group ...
Our meta-analysis revealed that IV N-acetylcysteine may be effective in reducing mortality of severe aluminum phosphide poisoning cases....
Registration number in Prospero CRD42022375344 on 25 NOVEMBER 2022, retrospectively registered....